Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor genome and microenvironment alteration by trastuzumab deruxtecan as neoadjuvant therapy for HER2-mutant NSCLC.

Scientific reports - 26 May 2026

Li Jiangyang, Lu Xianfeng, Yue Shuai, Hang Ruyi, Dai Xiaoyan, Kuang Xunjie, Guo Wei, Huang Zhou, Xiong Yanli, Li Mengxia

Abstract excerpt

Non-small cell lung cancer (NSCLC) patients carrying HER2 exon 20 insertion (HER2 20ins) are respond poorly to conventional therapies and pan HER inhibitors. Trastuzumab Deruxtecan (T-DXd) has been approved in second line treatment in advanced NSCLC, but its efficacy in operable patients remains unclear. Here, we report a case of a patient with operable, HER2 20ins NSCLC who received neoadjuvant T-DXd, along with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Camptothecin
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Immunoconjugates

Share to Neoadjuvant Therapy

Share to Trastuzumab

Share to Tumor Microenvironment

Share to Whole Genome Sequencing

Source

Open in PubMed Open full text

Identifiers

PMID: 42185382
DOI: 10.1038/s41598-026-53779-8
PMCID: PMC13434209

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor genome and microenvironment alteration by trastuzumab deruxtecan as neoadjuvant therapy for HER2-mutant NSCLC.PMID 42185382Read ↗

Tumor Genome and Microenvironment Alteration by Trastuzumab Deruxtecan as Neoadjuvant Therapy for HER2 Mutant NSCLCSemantic proximity Read ↗

Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy.Semantic proximity Read ↗

Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertionsSemantic proximity Read ↗

[Trastuzumab Deruxtecan for EGFR-mutant Lung Adenocarcinoma with Acquired High-level HER2 Amplification: A Case Report].Semantic proximity Read ↗

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.Semantic proximity Read ↗

Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma.Semantic proximity Read ↗

Mechanism of action and resistance to Trastuzumab Deruxtecan in patients with metastatic breast cancer: the DAISY trialSemantic proximity Read ↗

The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinomaSemantic proximity Read ↗

HER2 mutations in advanced cervical neuroendocrine carcinoma: implications for trastuzumab deruxtecan therapy.Semantic proximity Read ↗

Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC.Semantic proximity Read ↗

Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report.Semantic proximity Read ↗

FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.